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Abstract
Background: Gambogic acid (GA) is a major active ingredient of gamboge, a widely used traditional Chinese medicine
that has been reported to be a potent cytotoxic agent against some malignant tumors. Many studies have shown that the
NF-kappa B signaling pathway plays an important role in anti-apoptosis and the drug resistance of tumor cells during
chemotherapy. In this study, the effects and mechanisms of GA and the NF-kappa B inhibitor celastrol on oral cancer
cells were investigated.
Methods: Three human oral squamous cell carcinoma cell lines, Tca8113, TSCC and NT, were treated with GA alone,
celastrol alone or GA plus celastrol. Cytotoxicity was assessed by MTT assay. The rate of apoptosis was examined with
annexin V/PI staining as well as transmission electronic microscopy in Tca8113 cells. The level of constitutive NF-kappa
B activity in oral squamous cell carcinoma cell lines was determined by immunofluorescence assays and nuclear extracts
and electrophoretic mobility shift assays (EMSAs) in vitro. To further investigate the role of NF-kappa B activity in GA
and celastrol treatment in oral squamous cell carcinoma, we used the dominant negative mutant SR-IκBα to inhibit NF-
kappa B activity and to observe its influence on the effect of GA.
Results: The results showed that GA could inhibit the proliferation and induce the apoptosis of the oral squamous cell
carcinoma cell lines and that the NF-kappa B pathway was simultaneously activated by GA treatment. The minimal
cytotoxic dose of celastrol was able to effectively suppress the GA-induced NF-kappa B pathway activation. Following
the combined treatment with GA and the minimal cytotoxic dose of celastrol or the dominant negative mutant SR-IκBα,
proliferation was significantly inhibited, and the apoptotic rate of Tca8113 cells was significantly increased.
Conclusion: The combination of GA and celastrol has a synergistic antitumor effect. The effect can be primarily
attributed to apoptosis induced by a decrease in NF-kappa B pathway activation. The NF-kappa B signaling pathway plays
an important role in this process. Therefore, combining GA and celastrol may be a promising modality for treating oral
squamous cell carcinoma.
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Background
Despite improvements in surgery and radiation, the over-
all survival rate of patients with oral squamous cell carci-
noma (OSCC) has not improved over the past two
decades[1]. Chemotherapy (pre- or post-surgery) does not
appear to be beneficial for local control and survival
improvement in the patients with OSCC. Current chemo-
therapeutic agents have limited efficacy in oral cancer. To
overcome this problem, multiple chemotherapeutic
agents with different modes of action, used either alone or
in combination, have been suggested[2].
Gambogic acid (GA) is a major active ingredient of gam-
boge, which has been widely used in traditional Chinese
medicine. It is reported that GA possesses diverse biologi-
cal effects, such as anti-oxidant and anti-infectious activi-
ties[3]. Recent pharmacological studies have revealed that
GA also has potent cytotoxic and anti-cancer activities in
several cancer cell lines [4-8]. However, little is known
about the effect of GA on OSCC. In the present study, we
investigated and proved that the NF-kappa B pathway was
highly activated by GA treatment while inducing cell
apoptosis in OSCC. The minimal cytotoxic dose of celas-
trol effectively suppressed the GA-induced NF-kappa B
pathway activation and increased the anti-cancer effect of
GA.
Methods
Reagents
GA and celastrol were provided by Calbiochem (Ger-
many). Dimethyl sulfoxide (DMSO) was purchased from
Sigma Chemical Company (USA). The compounds were
dissolved in DMSO to generate a stock concentration of
100 mM. Subsequent dilutions were made in culture
medium. The same proportion of DMSO/culture medium
was added to the controls. The final DMSO content was
less than 0.1%. RPMI 1640 culture medium and fetal
bovine serum (FBS) were obtained from Gibco (USA). 3'-
(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bro-
mide (MTT), bovine serum albumin (BSA) and Hoechst
33342 were purchased from Sigma Chemical Company.
PI/RNase Staining Buffer and the Annexin V-FITC Apopto-
sis Detection Kit I were purchased from BD Pharmingen
(USA). The mouse monoclonal antibody against NF-
kappa B p65 was purchased from Santa Cruz Biotechnol-
ogy Incorporation (USA). NE-PER nuclear and cytoplas-
mic extraction reagents and the LightShift-TM
chemiluminescent EMSA kit were purchased from Pierce
Biotechnology (USA). Lipofectamine 2000 reagent was
purchased from Invitrogen (USA).
Cell lines
Three human oral squamous cell carcinoma cell lines
were included in the study. Tca8113 was established in
our laboratory. TSCC was a gift from the School of Stoma-
tology, Wuhan University, China. NT was a gift from
Nagasaki University, Japan. Cells were cultured in RPMI
1640 medium supplemented with 10% (v/v) FBS, 100
units/ml penicillin and 100 units/ml streptomycin at
37°C in a humidified atmosphere containing 5% CO2
[9,10].
Plasmid and transient transfection
Cells were plated in 6-well plates and transfected with
pBabe-SR-IκBα or pBabe using Lipofectamine 2000 rea-
gents according to the manufacturer's instructions (Invit-
rogen Life Technologies). Six hours after transfection, the
complex medium was replaced with RPMI 1640 medium
supplemented with 10% (v/v) FBS. After an additional 24
hours of incubation, cells were treated with or without
GA.
Cell viability assay
Cells were plated into a 96-well plate at a density of 1 ×
103/well and treated with the indicated dose of GA, celas-
trol or both after 24 hours of incubation. For the cell via-
bility assay, 20 μl of MTT dissolved in PBS (5 mg/ml) was
added to each well. The plates were further incubated for
4 hours. The absorbance of each well was measured using
an enzyme-linked immunosorbent assay reader at 490
nm after being dissolved in 150 μl of DMSO.
Transmission electron microscopy
Cells were cultured with or without 4 μM GA for 48 hours
and then immersed in cacodylate-buffered 2.5% glutaral-
dehyde at 4°C for 3 hours. Subsequently, cells were
washed for 1 hour in 0.1 M cacodylate buffer, pH 7.4,
fixed for 1 hour in buffered 1% osmium tetroxide, dehy-
drated in graded ethanol and embedded in Epon 812.
Thin sections (600 Å thick) were stained with uranyl ace-
tate and lead citrate and then observed with a Zeiss EM
900 transmission electron microscopy (Zeiss, Germany)
at 50 kV.
DNA content and cell cycle analysis
Cells were treated with 4 μM GA for different periods,
trypsinized, washed once with PBS and fixed in 70% eth-
anol for 2 hours at 4°C. After washing with PBS, fixed cells
were incubated with 0.5 ml PI/RNase staining buffer for
15 minutes at room temperature. DNA content and cell
cycle status were assessed by FACScan laser flow cytometry
(FACSCalibur, Becton Dickinson, USA). The data were
analyzed using MODFIT and CELLQUEST software.
Apoptotic cells were distinguished from non-apoptotic
intact cells by their decreased DNA content, as determined
by their lower PI staining intensity in the area below the
sub-G0/G1 phase.BMC Cancer 2009, 9:343 http://www.biomedcentral.com/1471-2407/9/343
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Annexin V/PI double-staining assay
Cells (1 × 106) were treated with the indicated dose of GA,
celastrol or a combination of both. Apoptotic cells were
identified by double supravital staining with recombinant
FITC-conjugated annexin V and PI using the Annexin V-
FITC apoptosis detection kit according to the manufac-
turer's instructions. Flow cytometry analysis was per-
formed immediately after supravital staining. Data
acquisition and analysis were performed by a Becton
Dickinson FACSCalibur flow cytometer using CellQuest
software. Cells that were annexin V (-) and PI (-) were con-
sidered viable cells. Cells that were annexin V (+) and PI
(-) were considered early-stage apoptotic cells. Cells that
were annexin V (+) and PI (+) were considered late-stage
apoptotic cells. Cells that were annexin V (-) and PI (+)
were considered necrotic cells.
Immunofluorescence
Cells were grown on coverslips and cultured for 24 hours.
After treatment with the indicated doses of GA, celastrol
or both for 12 hours, cells were fixed in 4% paraformalde-
hyde for 15 minutes, washed in PBS and treated for 15
minutes with PBS containing 0.1% Triton X-100. The cells
were then washed, blocked with 10% bovine serum albu-
min (BSA) for 1 hour at room temperature and incubated
at 4°C overnight with NF-kappa B p65 antibody (1:100)
diluted in 0.1% BSA. After extensive washing, a 1:200
dilution of FITC-conjugated goat anti-mouse IgG was
applied as the secondary antibody for 1 hour at room tem-
perature. Nuclear staining was achieved by incubating
cells in Hoechst 33342 for 5 minutes. The slides were then
washed and photographed with a laser scanning confocal
microscope (TCS SP2, Leica, Germany). The positive con-
trol was treated with 50 ng/ml TNF-α (Sigma-Aldrich,
USA) for 30 minutes.
Nuclear extracts and electrophoretic mobility shift assays 
(EMSAs)
Cells (1 × 106) were treated with the indicated doses of
GA, celastrol or both, and the nuclear extracts were pre-
pared using NE-PER nuclear and cytoplasm extraction rea-
gents according to the manufacturer's instructions.
Synthetic complementary oligonucleotides were 3'-bioti-
nylated using the biotin 3'-end DNA labeling kit (Pierce)
according to the manufacturer's instructions and
annealed for 2 hours at room temperature. The sequences
of the oligonucleotides for NF-kappa B were: 5' - AGT TGA
GGG GAC TTT CCC AGG C - 3' and 3' - TCA ACT CCC
CTG AAA GGG TCC G - 5'. The binding reaction was car-
ried out for 20 minutes at room temperature in the pres-
ence of 50 ng/μl poly (dI-dC), 0.05% Nonidet P-40, 5 mM
MgCl2, 10 mM EDTA and 2.5% glycerol in 1× binding
buffer (LightShift-TM chemiluminescent EMSA kit), using
20 fM biotin-end-labeled target DNA and 5 μg of nuclear
extract. Products were loaded onto native 4% polyacryla-
mide gels, pre-electrophoresed for 60 minutes in 0.5× Tris
borate/EDTA and then submitted to electrophoresis at
100 V before being transferred onto a positively charged
nylon membrane (HybondTM-N+) in 0.5× Tris borate/
EDTA at 100 V for 30 minutes. Transferred DNA was
cross-linked to the membrane at 120 mJ/cm2 and detected
using horseradish peroxidase-conjugated streptavidin
(LightShift-TM chemiluminescent EMSA kit), according
to the manufacturer's instructions.
Statistical analysis
All assays were repeated three times to insure reproduci-
bility. The significance of results obtained from the con-
trol and treated groups was analyzed using the paired
Student's t-test. The synergistic effects of GA and celastrol
were assessed using factorial ANOVA. Means and standard
deviations were calculated. P < 0.05 was regarded as statis-
tically significant.
Results
Effects of GA on cell viability
The MTT assay was performed to analyze the effects of GA
on the viability of Tca8113, TSCC and NT cells. As shown
in Figure 1, GA inhibited the growth of these three cell
lines in both a time- and dose-dependent manner. Over
time, more and more cells began to shrink, indicating
increased cell death induced by GA treatment. The IC50
values (the concentration of GA that results in a 50%
reduction in absorbance compared with the control) for
these three cell lines after 72 hours of treatment were cal-
culated based on the MTT assay. The IC50 of GA was 4.23
μM for Tca8113, 3.34 μM for TSCC and 3.76 μM for NT
cells.
Apoptotic changes following GA treatment
To elucidate whether the growth inhibitory effect of GA
was attributable to the induction of apoptosis, transmis-
sion electron microscopy, cell cycle analysis and flow
cytometric analysis with annexin V/PI double staining
were performed. First, transmission electron microscopy
was used to determine the subcellular changes evoked by
GA in Tca8113 cells. We observed that the nuclei of cells
exposed to 4 μM GA for 48 hours were pyknotic and that
some nuclei were fragmented. There were various vacu-
oles and "apoptotic bodies" in the intra-cytoplasm or
extra-cytoplasm (Figure 2a). Secondly, the cell cycle anal-
ysis of Tca8113 cells treated with 4 μM GA for 48 hours
and 72 hours demonstrated a distinct population of cells
with DNA content below the G1 phase (a sub-G1 peak),
indicating the presence of apoptotic cells (Figure 2b).
Finally, flow cytometric analysis with annexin V/PI dou-
ble staining revealed that treatment with 4 μM GA signifi-
cantly increased the percentage of both early and lateBMC Cancer 2009, 9:343 http://www.biomedcentral.com/1471-2407/9/343
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apoptotic cells in a time-dependent manner (Figure 2c) (P
< 0.05).
Activation of the NF-kappa B pathway in GA-induced 
apoptosis
To determine the effect of GA on the activity of the NF-
kappa B pathway in OSCC cells, the nuclear translocation
of the cytoplasmic NF-kappa B p65 subunit was examined
in Tca8113 cells by immunostaining. The results showed
that 12 hours of GA treatment stimulated NF-kappa B p65
nuclear translocation, as did 50 ng/ml TNF-α treatment
for 1 hour (Figure 3a). After GA treatment for 4, 8 and 16
hours, the effect of GA on the binding activity of NF-
kappa B to its consensus DNA oligonucleotide was also
examined by EMSA. As indicated in Figure 3b, GA treat-
ment caused a significant increase in NF-kappa B DNA
binding activity.
Synergistic effects of celastrol on GA-induced cytotoxicity
GA activated the NF-kappa B signaling pathway while
inducing cell apoptosis. A minimal dose of the NF-kappa
B inhibitor celastrol was used to block the GA-induced
activation of NF-Kappa B, with the goal of enhancing the
anti-cancer effect of GA on OSCC cells. As Figure 4a
shows, celastrol can effectively enhance the cytotoxicity of
GA in all three cell lines. The combined effects of celastrol
and GA on all of the cell lines were significant (P < 0.01),
as evaluated by factorial ANOVA.
Annexin V/PI double staining indicated that the enhanced
cytotoxicity of GA and celastrol resulted from increased
apoptosis in Tca8113 cells. Treatment with 0.5 μM celas-
trol alone did not induce a remarkable degree of cell
apoptosis, but upon co-treatment with GA, the number of
apoptotic cells significantly increased (P < 0.05 compared
Effects of GA on the viability of oral squamous cell carcinoma cell lines Figure 1
Effects of GA on the viability of oral squamous cell carcinoma cell lines. a: Three oral squamous carcinoma cell lines 
were treated with 0, 2, 3, 4, 5 and 6 μM of GA for 24 hours, 48 hours and 72 hours. The inhibitory effects of GA were shown 
in a time- and dose-dependent manner. b: Morphological changes of Tca8113 cells under phase contrast microscopic observa-
tion induced by 4 μM GA from 0 to 72 hours. (A: 0, B: 24 hours, C: 48 hours, D: 72 hours, 100×, original magnification).BMC Cancer 2009, 9:343 http://www.biomedcentral.com/1471-2407/9/343
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to cells treated with GA alone; Figure 4b). Similarly, when
GA was combined with a specific NF-kappa B inhibitor,
the dominant negative mutant pBabe-SR-IκBα, the prolif-
eration of Tca8113 cells was significantly inhibited com-
pared to cells treated with GA combined with pBabe
empty vector (Figure 4c).
Effects of celastrol on GA-induced activation of NF-kappa 
B
To determine whether the synergistic effect of celastrol
was mediated by suppression of the GA-induced NF-
kappa B activation, nuclear translocation of the NF-kappa
B p65 subunit was examined by immunofluorescence
after treatment with GA, GA plus celastrol and GA plus
pBabe-SR-IκBα. As Figure 5a and 5b show, both celastrol
and pBabe-SR-IκBα effectively blocked the GA-induced
nuclear translocation of the p65 subunit. The inhibition
of GA-induced NF-kappa B activity by celastrol was fur-
ther confirmed by EMSA (Figure 5c).
Discussion
Gambogic acid is a major ingredient of gamboge, a
brownish-orange resin exuded from the Asian Garcinia
hanburryi tree. The resin has been used as Chinese tradi-
tional medicine in China for hundreds of years to treat
cancers with little side effect. Recent experiments have
demonstrated that GA exhibits a general inhibitory effect
against various tumor cell lines [4-6]. However, little
information is available in the literature about the effect
and mechanism of this compound on the growth of
human oral squamous cell carcinomas. In this study, we
investigated the effects of GA on the growth of human
OSCC cell lines. Our results demonstrate that GA signifi-
cantly inhibits the viability of OSCC cells and induces
their apoptosis in a time- and dose-dependent manner.
These results suggest that GA could be a potential chemo-
therapeutic agent, like many other plant-derived natural
compounds [11].
The transcription factor, NF-kappa B, is well established as
a regulator of genes encoding cytokines, cytokine recep-
tors and cell adhesion molecules that drive immune and
inflammatory responses[12]. In recent years, NF-kappa B
activation has been linked to many aspects of tumorigen-
esis[13,14], including the control of apoptosis, cell cycle,
differentiation, cell adhesion, cell migration and angio-
Apoptotic changes in GA-treated OSCC cells Figure 2
Apoptotic changes in GA-treated OSCC cells. a: Morphological changes of Tca8113 cells under transmission electronic 
microscopy (A: control, B: early-stage apoptosis, C: middle-stage apoptosis, D: late-stage apoptosis, 4000 × 10 original magnifi-
cation). b: Flow cytometry analysis of DNA content in Tca8113 cells treated with 4 μM GA for 24 hours to 72 hours (*: the 
sub-G1 peak). Percentages of sub-G1 peak are labeled. c: The rates of cell apoptosis were measured by annexin V and PI stain-
ing and detected by flow cytometry. Percentages of early apoptosis (Lower Right region) and late apoptosis (Upper Right 
region) are labeled. Images are representative of three independent experiments.BMC Cancer 2009, 9:343 http://www.biomedcentral.com/1471-2407/9/343
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genesis. Five NF-kappa B family members have been iden-
tified in mammalian cells, including p105/p50 (NF-
kappa B1), p100/p52 (NF-kappa B2), p65 (REL A), c-REL
and RELB, which associate with one another to form vari-
ous heterodimeric and homodimeric combinations.
These proteins are regulated by inhibitors that bind to the
inhibitory subunit of the NF-kappa B (I-kappa B) family
of ankyrin domain-containing proteins, which include I-
kappa B α, I-kappa B β, I-kappa B γ and I-kappa B ε[12].
In a classic NF-kappa B signaling pathway, NF-kappa B
resides in the cytoplasm in an inactive state as a heterot-
rimer consisting of p50, p65 and I-kappa B α subunits.
Most carcinogens, inflammatory agents and tumor pro-
moters have been shown to activate NF-kappa B. In
response to an activation signal, the I-kappa B α subunit
is phosphorylated at serine residues 32 and 36, ubiquiti-
nated at lysine residues 21 and 22, and degraded through
the proteasome pathway, thus exposing the nuclear local-
ization signals on the p50-p65 heterodimer. The p65 sub-
unit is then phosphorylated, leading to nuclear
translocation and binding to a specific sequence in DNA,
which, in turn, results in gene transcription[15]. NF-
kappa B regulates the expression of several genes whose
products are involved in anti-apoptosis such as Bcl-xL,
cIAP and TRAF[16,17].
It has been found that many chemotherapeutic agents,
including taxol, doxorubicin, etoposide, cisplatin and
tamoxifen, can activate NF-kappa B[18]. The activation of
NF-kappa B can lead to resistance to apoptosis induced by
chemotherapeutic agents. Thus, while activating apopto-
sis, the same agent can also activate NF-kappa B[19,20],
Activation of NF-kappa B pathway in GA-induced apoptosis Figure 3
Activation of NF-kappa B pathway in GA-induced apoptosis. a: Nuclear translocation of p65 subunit of NF-kappa B in 
Tca8113 cells after treatment with GA or TNF-α (A: control, without nuclear staining, B: control, with nuclear staining, C: 12 
hours treatment with 4 μM GA, without nuclear staining, D: 12 hours treatment with 4 μM GA, with nuclear staining, E: 60 
minutes treatment with 50 ng/ml TNF-α, without nuclear staining, F: 60 minutes treatment with 50 ng/ml TNF-α, with nuclear 
staining). b: EMSA analysis of NF-kappa B binding activity in Tca8113 cells after 4 to 16 hours of treatment with 4 μM GA.BMC Cancer 2009, 9:343 http://www.biomedcentral.com/1471-2407/9/343
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which can prevent apoptosis and block the ability of ther-
apeutic agents to induce cell death. The recognized
method of GA's antitumor effect is its ability to bind and
interact with the transferrin receptor, and thus induce cell
apoptosis[8]. It is also suggested that GA has the ability to
repress telomerase activity, which inhibits the prolifera-
tion of tumor cells[5]. In this study, we examined the
effect of GA on the activation of NF-kappa B in OSCC
cells. The results clearly show that GA stimulates nuclear
translocation of NF-kappa B p65, up-regulates the DNA
binding activity of NF-kappa B, and thus activates the NF-
kappa B signaling pathway. Considering the role of NF-
kappa B in preventing apoptosis, we could hypothesize
that, when treated with GA, an apoptosis inducer, OSCC
cells activate the NF-kappa B signaling pathway to resist
the apoptosis-inducing effect. This process is similar to the
chemotherapy resistance caused by other chemotherapeu-
tic agents.
The pivotal role of the NF-kappa B pathway in the inhibi-
tion of cell apoptosis, strongly suggests that NF-kappa B
inhibitors would be useful in cancer therapy. In recent
years, it has been reported that some agents, mostly plant-
derived products, with tumor chemopreventative and
Synergistic effect of celastrol on GA-induced cytotoxicity Figure 4
Synergistic effect of celastrol on GA-induced cytotoxicity. a: Inhibitory effects of combined treatment with GA and 
celastrol on three oral squamous cell carcinoma cell lines. Cells were treated with different doses of GA (0, 2, 3 and 4 μM) and 
celastrol (0, 0.5 and 1 μM) for 72 hours. The interaction effects of GA and celastrol on all three cell lines were highly significant 
(P < 0.01, factorial ANOVA). b: Annexin V and PI staining of Tca8113 cells after treatment with 4 μM GA and 0.5 μM celastrol 
for 72 hours. The increase in apoptotic cells in combined treatment group was significant (P < 0.05, Student's t-test), compared 
with cells treated with GA alone. c: Inhibitory effects of Tca8113 cells after transient transfection with the dominant mutant 
pBabe-SR-IκBα (specific NF-Kappa B inhibitor) for 24 hours and treatment with 4 μM GA for 72 hours. Images are represent-
ative of three independent experiments.BMC Cancer 2009, 9:343 http://www.biomedcentral.com/1471-2407/9/343
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chemotherapeutic effects suppress the activation of NF-
kappa B[21]. Although some of these agents are known to
induce apoptosis, the most likely therapeutic conse-
quence of NF-kappa B inhibition is a reduced apoptotic
threshold. Therefore, a reasonable strategy is to use a NF-
kappa B inhibitor as an adjuvant with other modalities to
sensitize tumor cells to chemotherapeutic agents.
Celastrol is a novel compound that has demonstrated the
ability to inhibit cancer progression and down-regulate
NF-kappa B activity. It is also a natural product extracted
from the traditional Chinese medicine "Thunder of God
Vine"[22]. Celastrol has been shown to decrease NF-
kappa B activity in prostate cancer and leukemia
cells[23,24]. However, it had not previously been evalu-
ated as a potential chemotherapeutic sensitizer for head
and neck or other solid tumors. Our results show that a
low dose of celastrol (less than 2 μM) had no significant
cytotoxic effect on OSCC cells. However, celastrol had a
significant synergistic effect on GA-induced apoptosis in
OSCC cells. Our combined results show that celastrol
decreases NF-kappa B activity stimulated by GA and then
decreases the apoptotic threshold of OSCC cells and sen-
sitizes cells to GA-induced apoptosis by inhibiting the NF-
kappa B signaling pathway.
In most cases, the efficacy of chemotherapeutic agents is
limited due to toxicity and side effects. Therefore, increas-
ing the potency of chemotherapeutic agents remains a
worthy goal. Our results show that GA demonstrates anti-
tumor and apoptosis-inducing abilities in oral squamous
cell carcinoma cells. GA activates the NF-kappa B pathway
Effects of celastrol on GA-induced activation of NF-kappa B Figure 5
Effects of celastrol on GA-induced activation of NF-kappa B. a: Nuclear translocation of the p65 subunit of NF-kappa 
B in Tca8113 cells after 12 hours of treatment with 4 μM GA and 0.5 μM celastrol (A: control, without nuclear staining, B: con-
trol, with nuclear staining, C: 12 hours after treatment with 4 μM GA alone, without nuclear staining, D: 12 hours after treat-
ment with 4 μM GA alone, with nuclear staining, E: 12 hours after combined treatment with 4 μM GA and 0.5 μM celastrol, 
without nuclear staining, F: 12 hours after combined treatment with 4 μM GA and 0.5 μM celastrol, with nuclear staining). b: 
Nuclear translocation of the p65 subunit of NF-kappa B in Tca8113 cells after a 24 hours transient transfection of the dominant 
mutant pBabe-SR-IκBα and 12 hours treatment with 4 μM GA. (A: control, without nuclear staining, B: control, with nuclear 
staining, C: 24 hours transfection with pBαbe and 12 hours treatment with 4 μM GA, without nuclear staining, D: 24 hours 
transfection with pBabe and 12 hours treatment with 4 μM GA, with nuclear staining, E: 24 hours transfection with pBabe-SR-
IκBα and 12 hours treatment with 4 μM GA, without nuclear staining, F: 24 hours transfection with pBabe-SR-IκBα and 12 
hours treatment with 4 μM GA, with nuclear staining). c: EMSA analysis of NF-kappa B binding activity in Tca8113 cells after 12 
hours of treatment with 4 μM GA and 0.5 μM celastrol (A: control, B: after treatment with GA alone, C: after combined treat-
ment with GA and celastrol).BMC Cancer 2009, 9:343 http://www.biomedcentral.com/1471-2407/9/343
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while inducing apoptosis, thus blunting its own antitu-
mor effect. Celastrol has a synergistic effect on the GA-
induced apoptosis in oral cancer cells by inhibiting the
NF-kappa B activity stimulated by GA.
Conclusion
Our study suggests that a minimally toxic dose of celastrol
could enhance the cytotoxicity and apoptosis-inducing
effect of GA. These results indicate that GA's antitumor
effect could be amplified in a minimally toxic way by
inhibiting NF-kappa B activity in OSCC cells. Celastrol
may also be useful in combination therapies by enhanc-
ing the efficacy of chemotherapeutic agents with little tox-
icity or side effects.
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